18.09.2023 - New data demonstrates a therapeutic effect for at least 10 days after a single subcutaneously (SC) injection of an extended-release selective neuronal nitric oxide synthase (nNOS) inhibitor The slow-release formulation led to reversal of . Seite 1
Beyond Air, Inc (XAIR) Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Partnership provides access to hospitals in key Asia-Pacific countries Getz Healthcare will make a payment to Beyond Air upon receipt of CE Mark Beyond Air will receive royalty payments based on net sales GARDEN CITY, New York, Sept. 07, 2023 (GLOBE NEWSWIRE) Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patien
07.09.2023 - Partnership provides access to hospitals in key Asia-Pacific countries Getz Healthcare will make a payment to Beyond Air upon receipt of CE Mark Beyond Air will receive royalty payments based on net sales GARDEN CITY, New York, Sept. . Seite 1
Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region Partnership provides access to hospitals in key.